← Evidence map

ReviewCureus2024

Osimertinib in Early-Stage EGFR-Mutated Non-small Cell Lung Cancer: A Narrative Review of Its Impact on Survival, Safety, and Clinical Outcomes.

Mohammed Khaleel Almadhoun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Osimertinib in Early-Stage EGFR-Mutated Non-small Cell Lung Cancer: A Narrative Review of Its Impact on Survival, Safety, and Clinical Outcomes. | OpenQuestion